BlackRock
IMVT icon

BlackRock’s Immunovant IMVT Stock Holding History

BlackRock’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$277M Buy
7,180,897
+606,400
+9% +$18.5M ﹤0.01% 1592
2026
Q1 		$163M Buy
6,574,497
+516,281
+9% +$13.4M ﹤0.01% 1788
2025
Q4 		$154M Buy
6,058,216
+319,980
+6% +$7.14M ﹤0.01% 1848
2025
Q3 		$92.5M Sell
5,738,236
-110,049
-2% -$1.78M ﹤0.01% 2145
2025
Q2 		$93.6M Buy
5,848,285
+484,063
+9% +$7.32M ﹤0.01% 2091
2025
Q1 		$91.7M Buy
5,364,222
+221,151
+4% +$4.63M ﹤0.01% 2041
2024
Q4 		$127M Buy
5,143,071
+89,921
+2% +$2.55M ﹤0.01% 1942
2024
Q3 		$144M Buy
5,053,150
+137,023
+3% +$4.04M ﹤0.01% 1860
2024
Q2 		$130M Buy
4,916,127
+439,327
+10% +$12.5M ﹤0.01% 1878
2024
Q1 		$145M Sell
4,476,800
-53,916
-1% -$1.97M ﹤0.01% 1845
2023
Q4 		$191M Buy
4,530,716
+399,051
+10% +$14.7M ﹤0.01% 1678
2023
Q3 		$159M Sell
4,131,665
-69,649
-2% -$1.57M ﹤0.01% 1696
2023
Q2 		$79.7M Buy
4,201,314
+264,133
+7% +$4.93M ﹤0.01% 2200
2023
Q1 		$61.1M Buy
3,937,181
+7,757
+0.2% +$135K ﹤0.01% 2311
2022
Q4 		$69.7M Buy
3,929,424
+422,750
+12% +$5.32M ﹤0.01% 2242
2022
Q3 		$19.6M Sell
3,506,674
-124,636
-3% -$609K ﹤0.01% 3043
2022
Q2 		$14.2M Buy
3,631,310
+277,444
+8% +$1.2M ﹤0.01% 3298
2022
Q1 		$18.5M Buy
3,353,866
+28,865
+0.9% +$180K ﹤0.01% 3219
2021
Q4 		$28.3M Buy
3,325,001
+76,000
+2% +$627K ﹤0.01% 3050
2021
Q3 		$28.2M Buy
3,249,001
+146,214
+5% +$1.32M ﹤0.01% 3056
2021
Q2 		$32.8M Sell
3,102,787
-582,229
-16% -$8.13M ﹤0.01% 2989
2021
Q1 		$59.1M Sell
3,685,016
-1,114,571
-23% -$29.4M ﹤0.01% 2515
2020
Q4 		$222M Buy
4,799,587
+1,270,446
+36% +$58.7M 0.01% 1539
2020
Q3 		$124M Buy
3,529,141
+1,226,550
+53% +$36.9M ﹤0.01% 1745
2020
Q2 		$56.1M Buy
2,302,591
+1,399,624
+155% +$30M ﹤0.01% 2183
2020
Q1 		$14.1M Buy
902,967
+303,100
+51% +$4.56M ﹤0.01% 2802
2019
Q4 		$9.52M Buy
+599,867
New +$6.72M ﹤0.01% 3273

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BlackRock's IMVT Position: Q2 2026 in Review

BlackRock increased its Immunovant (IMVT) stake by 9.2% in Q2 2026, buying an estimated $18.5M and bringing the position to 7,180,897 shares worth $277M. The position accounts for ﹤0.01% of the portfolio, ranked #1592.

BlackRock first reported a position in IMVT in Q4 2019 and has held it in 27 quarters since. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • BlackRock held 7,180,897 shares of Immunovant worth $277M as of Q2 2026.
  • BlackRock bought 606,400 Immunovant shares in Q2 2026, an estimated $18.5M.
  • Immunovant made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #1592 holding.
  • BlackRock first reported a position in Immunovant in Q4 2019 and has held it in 27 quarters since.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.